BACKGROUND AND PURPOSE: Prevention or disease-modifying therapies are critical for the treatment of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and Huntington's disease. However, no such intervention is currently available. Growing evidence has demonstrated that administration of histone deacetylase (HDAC) inhibitors ameliorates a wide range of neurologic and psychiatric disorders in experimental models. Suberoylanilide hydroxamic acid (SAHA) was the first HDAC inhibitor approved by the Food and Drug Administration for the sole use of cancer therapy. The purpose of this study was to explore the potential new indications of SAHA for therapy of neurodegenerative diseases in in vitro Parkinson's disease models. EXPERIMENTAL APPROACH: Mesencephalic neuron-glia cultures and reconstituted cultures were used to investigate neurotrophic and neuroprotective effects of SAHA. We measured toxicity in dopaminergic neurons, using dopamine uptake assay and morphological analysis and expression of neurotrophic substances by enzyme-linked immunosorbent assay and real-time RT PCR. KEY RESULTS: In mesencephalic neuron-glia cultures, SAHA displayed dose- and time-dependent prolongation of the survival and protection against neurotoxin-induced neuronal death of dopaminergic neurons. Mechanistic studies revealed that the neuroprotective effects of SAHA were mediated in part by promoting release of neurotrophic factors from astroglia through inhibition of histone deacetylation. CONCLUSION AND IMPLICATIONS: The novel neurotrophic and neuroprotective effects of SAHA demonstrated in this study suggest that further study of this HDAC inhibitor could provide a new therapeutic approach to the treatment of neurodegenerative diseases. Published 2011. This article is a U.S. Government work and is in the public domain in the USA.
BACKGROUND AND PURPOSE: Prevention or disease-modifying therapies are critical for the treatment of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and Huntington's disease. However, no such intervention is currently available. Growing evidence has demonstrated that administration of histone deacetylase (HDAC) inhibitors ameliorates a wide range of neurologic and psychiatric disorders in experimental models. Suberoylanilide hydroxamic acid (SAHA) was the first HDAC inhibitor approved by the Food and Drug Administration for the sole use of cancer therapy. The purpose of this study was to explore the potential new indications of SAHA for therapy of neurodegenerative diseases in in vitro Parkinson's disease models. EXPERIMENTAL APPROACH: Mesencephalic neuron-glia cultures and reconstituted cultures were used to investigate neurotrophic and neuroprotective effects of SAHA. We measured toxicity in dopaminergic neurons, using dopamine uptake assay and morphological analysis and expression of neurotrophic substances by enzyme-linked immunosorbent assay and real-time RT PCR. KEY RESULTS: In mesencephalic neuron-glia cultures, SAHA displayed dose- and time-dependent prolongation of the survival and protection against neurotoxin-induced neuronal death of dopaminergic neurons. Mechanistic studies revealed that the neuroprotective effects of SAHA were mediated in part by promoting release of neurotrophic factors from astroglia through inhibition of histone deacetylation. CONCLUSION AND IMPLICATIONS: The novel neurotrophic and neuroprotective effects of SAHA demonstrated in this study suggest that further study of this HDAC inhibitor could provide a new therapeutic approach to the treatment of neurodegenerative diseases. Published 2011. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Eric Hahnen; Ilker Y Eyüpoglu; Lars Brichta; Kirsten Haastert; Christian Tränkle; Florian A Siebzehnrübl; Markus Riessland; Irmgard Hölker; Peter Claus; Johann Romstöck; Rolf Buslei; Brunhilde Wirth; Ingmar Blümcke Journal: J Neurochem Date: 2006-07 Impact factor: 5.372
Authors: Hantamalala Ralay Ranaivo; Jeffrey M Craft; Wenhui Hu; Ling Guo; Laura K Wing; Linda J Van Eldik; D Martin Watterson Journal: J Neurosci Date: 2006-01-11 Impact factor: 6.167
Authors: Angela Hodges; Andrew D Strand; Aaron K Aragaki; Alexandre Kuhn; Thierry Sengstag; Gareth Hughes; Lyn A Elliston; Cathy Hartog; Darlene R Goldstein; Doris Thu; Zane R Hollingsworth; Francois Collin; Beth Synek; Peter A Holmans; Anne B Young; Nancy S Wexler; Mauro Delorenzi; Charles Kooperberg; Sarah J Augood; Richard L M Faull; James M Olson; Lesley Jones; Ruth Luthi-Carter Journal: Hum Mol Genet Date: 2006-02-08 Impact factor: 6.150
Authors: Louise M Collins; Luc J Adriaanse; Surabhi D Theratile; Shane V Hegarty; Aideen M Sullivan; Gerard W O'Keeffe Journal: Mol Neurobiol Date: 2014-07-29 Impact factor: 5.590
Authors: Maxim Salganik; Valeriy G Sergeyev; Vishal Shinde; Craig A Meyers; Marina S Gorbatyuk; Jonathan H Lin; Sergey Zolotukhin; Oleg S Gorbatyuk Journal: Neurobiol Aging Date: 2015-03-05 Impact factor: 4.673